N‐terminal truncated pyroglutamyl β amyloid peptide Aβpy3‐42 shows a faster aggregation kinetics than the full‐length Aβ1‐42
- 26 June 2009
- journal article
- research article
- Published by Wiley in Peptide Science
- Vol. 91 (10), 861-873
- https://doi.org/10.1002/bip.21271
Abstract
We tested directly the differences in the aggregation kinetics of three important β amyloid peptides, the full-length Aβ1-42, and the two N-terminal truncated and pyroglutamil modified Aβpy3-42 and Aβpy11-42 found in different relative concentrations in the brains in normal aging and in Alzheimer disease. By following the circular dichroism signal and the ThT fluorescence of the solution in phosphate buffer, we found substantially faster aggregation kinetics for Aβpy3-42. This behavior is due to the particular sequence of this peptide, which is also responsible for the specific oligomeric aggregation states, found by TEM, during the fibrillization process, which are very different from those of Aβ1-42, more prone to fibril formation. In addition, Aβpy3-42 is found here to have an inhibitory effect on Aβ1-42 fibrillogenesis, coherently with its known greater infective power. This is an indication of the important role of this peptide in the aggregation process of β-peptides in Alzheimer disease. © 2009 Wiley Periodicals, Inc. Biopolymers 91: 861–873, 2009. This article was originally published online as an accepted preprint. The “Published Online“ date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.comKeywords
This publication has 44 references indexed in Scilit:
- Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of CalciumPublished by Elsevier BV ,2006
- Protein Misfolding, Functional Amyloid, and Human DiseaseAnnual Review of Biochemistry, 2006
- Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic ManagementAnnals of Internal Medicine, 2004
- Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanismsNeurobiology of Aging, 2002
- Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivoNature, 2002
- Kinetic partitioning of protein folding and aggregationNature Structural & Molecular Biology, 2002
- Presenilin-1 mutations in Alzheimer's diseaseNature, 2000
- Amyloid β-Protein and the Genetics of Alzheimer's DiseaseJournal of Biological Chemistry, 1996
- Water-soluble Aβ(N-40, N-42) Oligomers in Normal and Alzheimer Disease BrainsJournal of Biological Chemistry, 1996
- Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochemical and Biophysical Research Communications, 1984